165 related articles for article (PubMed ID: 23534242)
21. [Targeted therapies for connective tissue diseases and vasculitis].
Girard-Guyonvarc'h C; Iudici M
Rev Med Suisse; 2020 Mar; 16(685):487-491. PubMed ID: 32167250
[TBL] [Abstract][Full Text] [Related]
22. Woman in grey: hydroxychloroquine-induced hyperpigmentation.
Ivo R; Lopes CA; Reis R
BMJ Case Rep; 2018 Nov; 11(1):. PubMed ID: 30567137
[No Abstract] [Full Text] [Related]
23. Systemic lupus erythematosus and Sjögren's syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C.
Onishi S; Nagashima T; Kimura H; Matsuyama Y; Yoshio T; Minota S
Lupus; 2010 May; 19(6):753-5. PubMed ID: 20064909
[TBL] [Abstract][Full Text] [Related]
24. [Morphologic study of the microcirculation in connective tissue diseases].
Cantatore FP; Corrado A; Covelli M; Lapadula G
Ann Ital Med Int; 2000; 15(4):273-81. PubMed ID: 11202629
[TBL] [Abstract][Full Text] [Related]
25. [Primary Gougerot-Sjögren syndrome. Favourable effect of a fundamental treatment with hydroxychloroquine on biological anomalies].
Chaouat D; Aron Rosa D; Aron B
Rev Rhum Mal Osteoartic; 1988 Oct; 55(10):797-8. PubMed ID: 3194698
[No Abstract] [Full Text] [Related]
26. [Difficulties in differential diagnosis of Sjögren's syndrome and systemic lupus erythematosus].
Krawiec P; Batko B; Skura A; Adamek-Guzik T; Cześnikiewicz-Guzik M; Krzanowski M; Rydz-Stryszowska I; Ryszawa N; Guzik TJ
Przegl Lek; 2006; 63(5):278-83. PubMed ID: 17036505
[TBL] [Abstract][Full Text] [Related]
27. The management of collagen diseases.
Calin A
Ration Drug Ther; 1980 Jan; 14(1):1-5. PubMed ID: 7384531
[No Abstract] [Full Text] [Related]
28. Belimumab: review of use in systemic lupus erythematosus.
Boyce EG; Fusco BE
Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
[TBL] [Abstract][Full Text] [Related]
29. Recognition and management of Sjögren's syndrome: strategies for the advanced practice nurse.
Vale DL
Nurs Clin North Am; 2000 Mar; 35(1):267-78. PubMed ID: 10673580
[TBL] [Abstract][Full Text] [Related]
30. [Chloroquine cardiotoxicity in long-term lupus therapy in two patients].
Saussine A; Loriot MA; Picard C; Lecerf V; Landry J; Scheer I; Voicu S; Leenhardt A; Ducrocq G; Maubec E; Crickx B
Ann Dermatol Venereol; 2009; 136(6-7):530-5. PubMed ID: 19560616
[TBL] [Abstract][Full Text] [Related]
31. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
[TBL] [Abstract][Full Text] [Related]
32. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.
Pollard RP; Abdulahad WH; Bootsma H; Meiners PM; Spijkervet FK; Huitema MG; Burgerhof JG; Vissink A; Kroese FG
Ann Rheum Dis; 2013 Dec; 72(12):2048-50. PubMed ID: 23864239
[No Abstract] [Full Text] [Related]
33. The therapy of Sjogren's syndrome: a review.
Coaccioli S; Giuliani M; Puxeddu A
Clin Ter; 2007; 158(5):453-6. PubMed ID: 18062353
[TBL] [Abstract][Full Text] [Related]
34. Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.
Steinfeld SD; Youinou P
Expert Opin Biol Ther; 2006 Sep; 6(9):943-9. PubMed ID: 16918261
[TBL] [Abstract][Full Text] [Related]
35. [Influence of female sex on the respiratory manifestations of connective tissue disease].
Benveniste O; Herson S
Rev Pneumol Clin; 1999 Oct; 55(5):301-6. PubMed ID: 10637898
[TBL] [Abstract][Full Text] [Related]
36. Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients.
Fauchais AL; Ouattara B; Gondran G; Lalloué F; Petit D; Ly K; Lambert M; Launay D; Loustaud-Ratti V; Bezanahari H; Liozon E; Hachulla E; Jauberteau MO; Vidal E; Hatron PY
Rheumatology (Oxford); 2010 Jun; 49(6):1164-72. PubMed ID: 20299380
[TBL] [Abstract][Full Text] [Related]
37. Sjogren's syndrome-onset lupus patients have distinctive clinical manifestations and benign prognosis: a case-control study.
Xu D; Tian X; Zhang W; Zhang X; Liu B; Zhang F
Lupus; 2010 Feb; 19(2):197-200. PubMed ID: 19900977
[TBL] [Abstract][Full Text] [Related]
38. B cell depletion therapy in rheumatic disease.
Edwards JC; Cambridge G; Leandro MJ
Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):915-28. PubMed ID: 16980214
[TBL] [Abstract][Full Text] [Related]
39. [Primary Gougerot-Sjögren syndrome with necrotizing polymyositis: favorable effect of hydroxychloroquine].
Ponge T; Mussini JM; Ponge A; Forgeau Y; Barrier J; Cottin S; Grolleau JY
Rev Neurol (Paris); 1987; 143(2):147-8. PubMed ID: 3602794
[TBL] [Abstract][Full Text] [Related]
40. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H
Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
